NMN (Nicotinamide Mononucleotide) for Women's Health

TL;DR
The strongest metabolic outcome data for NMN in humans come from a randomised controlled trial in postmenopausal women with prediabetes. Ten weeks of 250 mg/day NMN improved muscle insulin sensitivity and insulin signalling. This makes Women’s Health one of the better-supported demographic applications for NMN at present. Evidence rating: ⭐⭐⭐⭐ Strong for muscle insulin sensitivity in this specific population.

Evidence Rating: ⭐⭐⭐⭐ Strong for improving muscle insulin sensitivity in postmenopausal women with prediabetes (Yoshino 2021); broader women’s health outcomes remain less studied.

What the Research Shows for Women’s Health

The landmark 2021 study by Yoshino et al., published in Science, remains the highest-profile human trial of NMN with a clear clinical metabolic endpoint. In postmenopausal women who were overweight or obese and had prediabetes, 250 mg of NMN daily for 10 weeks significantly increased insulin-stimulated glucose disposal in skeletal muscle and enhanced insulin signalling pathways (AKT and mTOR phosphorylation). Hepatic and adipose insulin sensitivity were unchanged, indicating a muscle-specific effect.

This finding is particularly relevant for women navigating midlife metabolic changes.

Key Benefits

  • Improved muscle insulin sensitivity in postmenopausal women with prediabetes
  • Enhanced insulin signalling in skeletal muscle
  • Reliable increase in NAD+ pathway activity
  • Generally well tolerated in the studied population

Key Study

  • Yoshino M. et al. (2021) — Randomised, placebo-controlled, double-blind trial. 25 postmenopausal women with overweight/obesity and prediabetes received 250 mg NMN or placebo daily for 10 weeks. Muscle insulin sensitivity increased significantly in the NMN group. Science, 372(6547), 1224–1229. DOI: 10.1126/science.abe9985

Supporting NAD+-raising and functional data from other trials (Igarashi 2022, Yi 2023, Morifuji 2024) provide additional context for midlife and older women.

Expert Views

The Yoshino trial involved collaboration with researchers including Shin-Ichiro Imai, a leading figure in NAD+ and ageing biology. The results have been widely discussed in metabolic and longevity research circles as one of the clearer human translational findings for NMN.

NZ Context for Women’s Health

Metabolic health and insulin sensitivity become increasingly important considerations for many New Zealand women from perimenopause onward. NMN is one option some explore alongside diet, resistance training and medical care.

Recommended Dosage

  • Dose used in the key trial: 250 mg per day
  • Other trials have used 300–900 mg
  • Consistency over weeks appears important for metabolic effects

Safety Notes

Well tolerated in the Yoshino trial and other human studies. As with any supplement, consult your healthcare provider before use, especially if you have diabetes, take glucose-lowering medication, or have other medical conditions.

This is not medical advice. BioHackNZ provides general information based on published research. NMN is a complementary supplement and is not intended to diagnose, treat, cure, or prevent any disease. Always consult your healthcare provider before starting any supplement regimen. Individual results vary.

Last updated: 22 August 2026 | BioHackNZ Research Team

Shop Nicotinamide Mononucleotide (NMN)
View Product →